Acta Scientific Microbiology (ISSN: 2581-3226)

Research Article Volume 6 Issue 7

Antibacterial Therapy Used in the Treatment of Bloodstream Infections Caused by Methicillin-Sensitive and Resistant Staphylococcus aureus

Elaine Cristina Birssi1, Daniela Dambroso-Altafini2, Cecilia Saori Mitsugui2, James Albiero1, Fabrícia Gimenes1, Patrícia de Mattos Andriato3, Heloisa Moreira Dias Pereira1, Giuliana Zardeto4 and Maria Cristina Bronharo Tognim1*

1Department of Basic Health Sciences, State University of Maringá, Maringá, Paraná, Brazil

2Maringá University Hospital, State University of Maringá, Maringá, Paraná, Brazil

3Department of Therapeutic Pharmacology, State University of Maringá, Paraná, Brazil

4University of Paraná, Umuarama, Paraná, Brazil

*Corresponding Author: Maria Cristina Bronharo Tognim, Department of Basic Health Sciences, State University of Maringá, Maringá, Paraná, Brazil.

Received: June 07, 2023; Published: June 23, 2023


Methicillin-susceptible Staphylococcus aureus or methicillin-resistant Staphylococcus aureus (MSSA or MRSA) sensitive or resistant to oxacillin are the main causative agents of bloodstream infection (BSI) and are associated with high rates of morbidity and mortality worldwide. The aim of the present study was to analyze the frequency of MSSA and MRSA isolates recovered from patients with BSI and to evaluate the main antibacterials used in the treatment. We retrospectively evaluated data from 98 patients who had BSI (22 MRSA BSI and 76 MSSA BSI) hospitalized in different sectors of a hospital between 2013 and 2021. The 98 S. aureus isolates evaluated were sensitive to vancomycin, linezolid, gentamicin, daptomycin, teicoplanin and rifamycin. The median length of stay was 27.5 and 19 days for patients with MRSA BSI and MSSA BSI, respectively. The mean number of antibacterials used per patient was approximately 5 for patients with MRSA BSI and 6 for patients with MSSA BSI. In the analysis of the antibacterial therapy used before and after the detection of MSSA BSI and MRSA BSI, we observed that most patients were already on the appropriate antibacterial therapy or had their therapy adjusted after detection. For patients with MRSA BSI, adjustment was performed mainly with vancomycin or linezolid. For patients with MSSA BSI, the therapeutic adjustment was performed using oxacillin, vancomycin and linezolid. In relation to patients who had MRSA BSI, in 7 of them other bacteria were isolated from the urine, catheter tip, endotracheal aspirate and/or blood. Of these patients, only 2 survived (29%). However, of the 11 patients who had only MRSA infection, 9 survived (82%). Our data suggest that the simultaneous presence of S. aureus and other bacteria may lead to worse clinical outcomes. We also evidenced a high consumption of antibacterials per patient and that although the median length of stay was higher for patients with MRSA BSI, the average use of antibacterials was slightly higher in patients with MSSA BSI. Thus, we conclude that there is a need to improve the management of antibacterial therapies, diagnostic methods and measures to control and prevent BSI by MRSA and MSSA.

Keywords: Staphylococcus aureus; MSSA and MRSA; Bloodstream Infection; Co-infection; Antimicrobials


  1. Santos S., et al. “Molecular epidemiology of Staphylococcus aureus in Brazil: high frequency of international epidemic pandemic clones, CA-MRSA and perspectives”. Brazilian Journal of Development 7 (2021): 35734-35751.
  2. Riche CVW., et al. “Epidemiology and risk factors for mortality among methicillin-resistant Staphylococcus aureus bacteremic patients in Southern Brazil”. Plos One 18 (2023): e0283774.
  3. Kourtis AP., et al. “Emerging Infections Program MRSA Author Vital signs: epidemiology and recent trends in methicillin-resistant and in methicillin- susceptible Staphylococcus aureus bloodstream infections—United States”. Morbidity and Mortality Weekly Report 68 (2019): 214-219.
  4. Liang BS., et al. “Antimicrobial resistance and prevalence of CVfB, SEK and SEQ genes among Staphylococcus aureus isolates from pediatric patients with bloodstream infections”. Experimental and Therapeutic Medicine 14 (2017): 5143-5148.
  5. Lisowska-Lysiak K., et al. “Epidemiology and Pathogenesis of Staphylococcus Bloodstream Infections in Humans: a Review”. Clinical Microbiology Reviews 70 (2021): 13-23.
  6. Lakhubdi S., et al. “Methicillin-resistant Staphylococcus aureus: molecular characterization, evolution, and epidemiology”. Clinical Microbiology Reviews 31 (2018): e0002018.
  7. Rose W., et al. “Current Paradigms of Combination Therapy in Methicillin-Resistant Staphylococcus aureus (MRSA) Bacteremia: Does it Work, Which Combination and for Which Patients?” Clinical Infectious Diseases 73 (2021): 2353-2360.
  8. Holland , et al. “Consideration for clinical trials of Staphylococcus aureus bloodstream infection in adults”. Clinical Infectious Diseases 68 (2019): 865-872.
  9. Van den Bosch CM., et al. “Appropriate antibiotic use reduces length of hospital stay”. Journal of Antimicrobial Chemotherapy 72 (2017): 923-932.
  10. Gradel K., et al. “Impact of appropriate empirical antibiotic treatment on recurrence and mortality in patients with bacteraemia: a population-based cohort study”. MC infectious diseases 17 (2017): 1-9.
  11. Dambroso-Altafini D., et al. “Overuse of empirical antibiotics in a COVID-19 intensive care unit led to the spread of carbapenem-resistant Gram-negative bacteria in a teaching hospital”. Journal of Global Antimicrobial Resistance 30 (2022): 100-102.
  12. World Health “Who publishes list of bacteria for which new antibiotics are urgently needs”. (2017).
  13. Porto J., et al. “Active surveillance to determine the impact of methicillin resistance on mortality in patients with bacteremia and influences of the use of antibiotics on the development of MRSA infection”. Revista da Sociedade Brasileira de Medicina Tropical 46 (2013): 713-718.
  14. Nurjad D., et al. “Phenotypic detection of hemin-inducible trimethoprim-sulfamethoxazole heteroresistance in Staphylococcus aureus”. Microbiology Spectrum 9 (2021): e01510-21.
  15. Piérard D., et al. “In vitro activity of ceftaroline and comparators against bacterial isolates collected globally from patients with skin infections”. Journal of Global Antimicrobial Resistance 26 (2021): 4-10.
  16. Klenk , et al. “The synergies of microorganisms enlightened - convergent approaches to delineating coinfections”. Pathogens and Disease 69 (2013): 71.
  17. Song , et al. “Pharmacokinetic/Pharmacodynamic Target Attainment of Vancomycin, at Three Reported Infusion Modes, for Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections in Critically Ill Patients: Focus on Novel Infusion Mode”. Frontiers in Cellular and Infection Microbiology (2022): 798.
  18. Tsai CE., et al. “Evaluation of the synergistic effect of ceftaroline against methicillin-resistant Staphylococcus aureus”. International Journal of Infectious Diseases 122 (2022): 230-236.
  19. Tong SY., et al. “Effect of vancomycin or daptomycin with vs without an antistaphylococcal β- lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial”. Jama 323 (2020): 527-537.
  20. La YJ., et al. “Comparison of clinical outcomes for glycopeptides and beta-lactams in methicillin-susceptible Staphylococcus aureus bloodstream infections”. Open Forum Infectious Diseases. US: Oxford University Press (2022): ofac 1457.
  21. Agnello S., et al. “Clinical outcomes of daptomycin versus anti-staphylococcal beta-lactams in definitive treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections”. International Journal of Antimicrobial Agents (2021):


Citation: Maria Cristina Bronharo Tognim., et al. “Antibacterial Therapy Used in the Treatment of Bloodstream Infections Caused by Methicillin-Sensitive and Resistant Staphylococcus aureus". Acta Scientific Microbiology 6.7 (2023): 52-59.


Copyright: © 2023 Maria Cristina Bronharo Tognim., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate30%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 30th, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US